drugset / Trial / NCT04891718

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

NCT04891718

NaSingle-groupOpen-labelBasic science

Summary

This is a multi-center, open-label Phase 0 Master Protocol in Australia designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumour microenvironment (TME) when administered intratumourally in microdose quantities via the CIVO device in patients with surface accessible solid tumours for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.

Timeline

Start
2021-09-15
Primary completion
2022-06-05
Completion
2022-06-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody Other
Subject TAK-186 Unknown Other

Indications